Resveratrol induces apoptosis through modulation of the Akt/FoxO3a/Bim pathway in HepG2 cells

Molecular Medicine Reports

Volumn 13, Issue 2, 2016, Pages 1689-1694

  Liu, Mi Hua ^a   Lin, Xiao Long ^b   Li, Jian ^c   He, Jun ^a   Tan, Tian Ping ^a   Wu, Shao Jian ^a   Yu, Shan ^a   Chen, Li ^a   Liu, Jun ^a   Tian, Wei ^a   Chen, Yu Dan ^a   Fu, Hong Yun ^a   Yuan, Cong ^d   Zhang, Yuan ^e  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c Boai Hospital of Zhongshan Affiliated to Southern Medical University   (China)

^d Department of Neurosurgery The First Hospital of Changsha   (China)

^e Hunan Provincial Mawangdui Hospital   (China)

Author keywords

Apoptosis; Forkhead box O3a; High glucose; Oxidative stress; Resveratrol

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BIM PROTEIN; FIBROBLAST GROWTH FACTOR 2; PROTEIN KINASE B; RESVERATROL; TRANSCRIPTION FACTOR FKHRL1; APOPTOSIS REGULATORY PROTEIN; BCL2L11 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MTT ASSAY; OXIDATIVE STRESS; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL NUCLEUS; CELL SURVIVAL; DRUG EFFECTS; HEP-G2 CELL LINE; METABOLISM; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; CELL NUCLEUS; CELL SURVIVAL; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; HEP G2 CELLS; HUMANS; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STILBENES;

EID: 84956895363     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4695     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Gao Q, Shi Y, Wang X, Zhou J, Qiu S and Fan J: Translational medicine in hepatocellular carcinoma. Front Med 6: 122-133, 2012.
3. Pervaiz S and Holme AL: Resveratrol: Its biologic targets and functional activity. Antioxid Redox Signal 11: 2851-2897, 2009.
4. Foti Cuzzola V, Ciurleo R, Giacoppo S, Marino S and Bramanti P: Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: Focus on recent discoveries. CNS Neurol Disord Drug Targets 10: 849-862, 2011.
5. Zordoky BN, Robertson IM and Dyck JR: Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 1852: 1155-1177, 2015.
6. Signorelli P and Ghidoni R: Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 16: 449-466, 2005.
7. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M and Sinclair D: Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689, 2004.
8. Delmas D, Jannin B, Cherkaoui Malki M and Latruffe N: Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep 7: 847-852, 2000.
9. Parekh P, Motiwale L, Naik N and Rao KV: Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol 63: 167-173, 2011.
10. Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL and Chen CS: Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther 7: 800-808, 2008.
11. Khan A, Aljarbou AN, Aldebasi YH, Faisal SM and Khan MA: Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway. Cancer Epidemiol 38: 765-772, 2014.
12. Nho RS and Hergert P: FoxO3a and disease progression. World J Biol Chem 5: 346-354, 2014.
13. Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol Protects PC12 cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a pathway. Cell Mol Neurobiol 35: 513-522, 2015.
14. Polter A, Yang S, Zmijewska AA, van Groen T, Paik JH, Depinho RA, Peng SL, Jope RS and Li X: Forkhead box, class O transcription factors in brain: Regulation and behavioral manifestation. Biol Psychiatry 65: 150-159, 2009.
15. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, et al: FOXO3a-dependent mechanism of E1A-Induced chemosensitization. Cancer Res 71: 6878-6887, 2011.
16. Wang JG, Zheng XX, Zeng GY, Zhou YJ and Yuan H: Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma. Oncol Rep 31: 488-496, 2014.
17. Carbajo-Pescador S, Steinmetz C, Kashyap A, Lorenz S, Mauriz JL, Heise M, Galle PR, González-Gallego J and Strand S: Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer 108: 442-449, 2013.
18. He L, Yang X, Cao X, Liu F, Quan M and Cao J: Casticin induces growth suppression and cell cycle arrest through activation of FOXO3a in hepatocellular carcinoma. Oncol Rep 29: 103-108, 2013.
19. Izzotti A: Molecular medicine and the development of cancer chemopreventive agents. Ann N Y Acad Sci 1259: 26-32, 2012.
20. Pirola L and Fröjdö S: Resveratrol: One molecule, many targets. IUBMB Life 60: 323-332, 2008.
21. Tzivion G, Dobson M and Ramakrishnan G: FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813: 1938-1945, 2011.
22. Hong ZY, Lee HJ, Shin DY, Kim SK, Seo M and Lee EJ: Inhibition of Akt/FOXO3a signaling by constitutively active FOXO3a suppresses growth of follicular thyroid cancer cell lines. Cancer Lett 314: 34-40, 2012.
23. Roy SK, Chen Q, Fu J, Shankar S and Srivastava RK: Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS One 6: e25166, 2011.